| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802814401022 | 281440102 | CEFTAZIDIME/KABI PD.INJ.SOL 1000MG/VIAL BTx10VIALS x 1000MG | 14.44 | 15.15 | 20.88 |
| 05/2018 | 2802814402029 | 281440202 | CEFTAZIDIME/KABI PD.I.S.INF 2000MG/VIAL BTx10VIALSx2000MG | 17.35 | 18.20 | 25.08 |
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
Ceftazidime overdosage has occurred in patients with renal failure. Reactions have included seizure activity, encephalopathy, asterixis, neuromuscular excitability, and coma.
The absorption of ceftazidime is directly proportional to the size of the dose.
Half-life, following IV administration, is approximately 1.9-hours. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function.
The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine.
* 115 mL/min